Rare Disease Genetic Testing Market Research Reveals Path To $2.18 Billion By 2030

The rare disease genetic testing market is gaining considerable attention as advancements in technology and personalized healthcare continue to evolve. With increasing demand for tailored medical treatments and improvements in genomic analysis, this sector is expected to experience strong growth. Let's explore the market's projected size, key players, emerging trends, and segment classifications to understand its future trajectory.

Projected Growth and Market Size of Rare Disease Genetic Testing
The market for rare disease genetic testing is anticipated to expand swiftly, reaching a valuation of $2.18 billion by 2030. This represents a compound annual growth rate (CAGR) of 13.1%. Several factors contribute to this rapid increase, including the rising emphasis on personalized medicine, growing investments in genomic data analytics, broader implementation of population-scale genetic screening, and the integration of genetics into everyday clinical practice. Additionally, innovations in bioinformatics platforms are playing a critical role in enhancing testing capabilities. Emerging trends over the forecast period comprise greater utilization of next-generation sequencing for rare disease diagnosis, expanded applications of AI-driven variant interpretation, development of more comprehensive genetic testing panels, closer integration of genetic data with clinical decision support systems, and a heightened focus on achieving early and precise diagnoses.

The rare disease genetic testing market size has grown rapidly in recent years. It will grow from $1.17 billion in 2025 to $1.33 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to improvements in genomic sequencing technologies, expansion of rare disease research initiatives, rising awareness of genetic disorders, availability of specialized diagnostic laboratories, growth in clinical genetics programs.

Download a free sample of the rare disease genetic testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies in the Rare Disease Genetic Testing Space
Several prominent organizations are influential players within this market, including Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Artemis DNA Inc., BGI Genomics Co. Ltd., GeneDx Inc., and Genomics England Ltd. A notable development took place in August 2024 when Labcorp, a US-based diagnostics and life sciences provider, acquired selected assets of Invitae. Although the financial details were not disclosed, this acquisition aims to strengthen Labcorp's genetic testing portfolio by incorporating Invitae's advanced technologies focused on oncology and select rare diseases. This move intends to provide deeper genomic insights to aid diagnosis, support treatment decisions, and enable personalized patient care. Invitae itself is recognized for its expertise in medical and hereditary genetic testing across a wide range of inherited and rare conditions.

Innovations and Trends Influencing the Rare Disease Genetic Testing Industry
Companies leading the rare disease genetic testing market are prioritizing the development of cutting-edge digital genomics platforms. These advanced software solutions combine genomic data analysis, interpretation, and reporting into one streamlined system, improving the speed, precision, and scalability of rare disease diagnostics. For example, in March 2025, Strand Life Sciences Private Limited, a software firm based in India, unveiled its StrandOmics Portal. This digital platform enhances diagnostic accuracy by providing clinicians with detailed insights into genetic variants, facilitating quicker and more exact diagnoses. It supports sophisticated variant interpretation, including prenatal testing, and allows for independent reviews of genetic information. The launch of this portal highlights the sector's commitment to precision medicine and equipping healthcare professionals with tools to improve patient outcomes.

View the full rare disease genetic testing market report:
https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Comprehensive Segmentation of the Rare Disease Genetic Testing Market
The market can be broken down into various segments to better understand its structure. By disease type, it includes categories such as immunological disorders, cardiovascular disorders, neurological diseases, endocrine and metabolism disorders, hematological diseases, dermatological diseases, and other conditions. In terms of technology, the market comprises next-generation sequencing, Sanger sequencing, polymerase chain reaction (PCR)-based testing, array-based testing, fluorescence in situ hybridization (FISH), and other related technologies. The specialty segment covers molecular genetic tests, chromosomal genetic tests, and biochemical genetic tests. End users of these tests include hospitals and clinics, research laboratories and contract research organizations, diagnostic laboratories, as well as other users.

Detailed Subsegments by Disease Categories
Further refinement within these disease types identifies specific subcategories. Immunological disorders include autoimmune diseases, allergic conditions, primary immunodeficiency disorders, and inflammatory disorders. Cardiovascular disorders encompass congenital heart defects, cardiomyopathies, aortic aneurysms, and pulmonary hypertension. Neurological diseases involve neurodegenerative disorders, neuromuscular disorders, epileptic syndromes, and movement disorders. Endocrine and metabolism disorders cover inherited metabolic disorders, thyroid diseases, adrenal disorders, and diabetes-related genetic conditions. Hematological diseases include hemophilia, thalassemia, sickle cell disease, and clotting disorders. Dermatological disease subtypes consist of genetic skin disorders, connective tissue diseases, pigmentary disorders, and keratinization disorders. Other disease types cover skeletal dysplasia, renal genetic disorders, ophthalmic genetic conditions, and gastrointestinal genetic conditions.

This detailed segmentation offers a clear framework for understanding the diverse and complex nature of the rare disease genetic testing market, its rapid growth, and the innovations poised to transform the field over the coming years.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.